论文部分内容阅读
化学治疗是非霍奇金淋巴瘤(Non-Hodgkins’lymphoma,NHL)的治愈性手段,但传统的标准化疗方案治愈率不到40%[1],在化疗无效的难治性复发性NHL中,15%～50%使用大剂量化疗联合自体外周血造血干细胞移植(ASCT)可达长期无瘤生存[21]。新的化疗药物和新的生物治疗模式的出现如单克隆抗体(McAb)及放免靶向治疗的临床应用对进一步提高NHL的治疗疗效带来了新的希望。2004年NCCN在淋巴瘤的治疗指引中,将氟达拉滨和Rituximab作为治疗中低度恶性淋巴瘤的一线药物,把放免靶向治疗Bexxar和Zevalin作为B细胞淋巴瘤的二线治疗方案。本文主要介绍治疗非霍奇金淋巴瘤的新的药物和方法。
Chemotherapy is a curative method for Non-Hodgkins lymphoma (NHL), but the cure rate of traditional standard chemotherapy regimen is less than 40% [1]. In chemotherapy-refractory and refractory recurrent NHL, High-dose chemotherapy combined with autologous peripheral blood stem cell transplantation (ASCT) can achieve long-term, tumor-free survival in 15% to 50% of patients [21]. The emergence of new chemotherapeutic drugs and new biotherapeutic modalities such as monoclonal antibody (McAb) and the clinical application of radioimmunotherapy targeted therapy have brought new hope to further improve the therapeutic effect of NHL. 2004 NCCN guidelines in the treatment of lymphoma, fludarabine and Rituximab as a first-line treatment of low-grade malignant lymphoma, the radioimmunotherapy Targeted Bexxar and Zevalin as a second-line treatment of B cell lymphoma. This article describes the new drugs and methods for the treatment of non-Hodgkin’s lymphoma.